App-Quantinova.ai

Lack of β‐catenin in Hepatocytes Impairs Proliferation and Promotes Liver Progenitor Cell‐Mediated Repair in Response to the Choline‐Deficient Ethionine‐Supplemented Diet

Jacquelyn Russell - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Chronic Liver Disease

Tamoxifen

The delivery of stem cell therapy to extended criteria donor human livers using normo‐ thermic machine perfusion

Richard W. Laing - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Interleukin

Establishing an Alcohol Liaison Service (ALS): Provision of tailored care and Improvement in Clinical Outcomes

Claire Kelly - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Substance Abuse

Alcohol Dependence

N/A

The Cost‐effectiveness of General Population HCV Screening in India

Antoine Chaillon - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

HCV Treatment with Direct‐Acting Antivirals in India is Cost‐Saving

Antoine Chaillon - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Profiling the endogenous and xenobiotic metabolome in a porcine model of acetaminophen induced acute liver failure

Rebecca L. Dargue - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fulminant hepatic failure

Acetaminophen

Phase 1, Randomized, Placebo Controlled Study of Givosiran, an Investigational RNA Interference (RNAi) Therapeutic, in Patients with Acute Intermittent Porphyria: Interim study results

Eliane Sardh - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute intermittent porphyria

ALN-AS1

Heterozygous Carriage of the Alpha1‐ antitrypsin PiZ Variant Increases the Risk to Develop Liver Fibrosis

Pavel Strnad - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Diabetes

N/A

An Ongoing Extension of a Phase 2 Study of WTX101 in Newly Diagnosed Wilson Disease Patients

Michael L. Schilskv - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Wilson disease

Tetrathiomolybdate

Sequence analysis of exon 1 of the ferritin light chain (FTL) gene can reveal the rare but benign diagnosis of ‘hereditary hyperferriti‐ naemia without cataracts’

Meha Bhuva - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Cataract

N/A

UK Biobank Study of Liver Iron Overload Shows Variable Penetrance of Different Genotypes

Andrew G. McKay - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hemochromatosis

N/A

Excretion of WTX101 (bis‐choline tetrathiomo‐ lybdate) after intravenous administration in rat models

Tom Plltz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Wilson disease

Tetrathiomolybdate

Ribosomal Stalling Causes Wilson Disease in Patients with Synonymous ATP7B Variant

Andr Viveiros - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Wilson disease

N/A

EXPLORE: A Prospective, Multinational Natural History Study of Patients with Acute Hepatic Porphyria (AHP) with Recurrent Attacks

Laurent Gouya - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute hepatic porphyria

Porphyrin

Lactobacillus Casei Shirota (LCS; Yakult) vs Placebo in patients with well‐compensated cirrhosis: A double‐blind, randomized controlled study

Jane Macnauahtan - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Systemic inflammation

N/A

Antiviral therapy in HCV infected patients prevents relapse of diffuse Large B cell Lymphoma

Adriano M. Pellicelli - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

Interferon

Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)

Maria Buti - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Osteoporosis

Tenofovir disoproxil fumarate

Safety, Tolerability and Pharmacokinetics of GSK3389404, an Antisense Oligonucleotide for the Treatment of Chronic Hepatitis B (CHB) Infection: A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation, First Time in Human Study

Kelong Han - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

IONIS HBV LRx

Safety and Efficacy of Vesatolimod (GS‐9620) in Patients with Chronic Hepatitis B (CHB) Who Are Not Currently on Antiviral Treatment

Kosh Aaarwal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Vesatolimod

Long‐Term Follow Up of Patients with Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver‐Related Morbidity and Mortality After Achieving SVR with DAA‐Based Therapy: Results from the Gilead SVR Registry

Marc Bourlire - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Liver cancer

N/A

Filters

45280 Abstracts